GET DAILY SIGNALSTandem Diabetes Care (TNDM) Delivers Solid Q3 Results Amid Business Transition
Key Takeaways
- Worldwide sales rose 14% year over year to $283.7 million, beating analyst consensus estimates.
- Net loss narrowed to $7.1 million, or $0.10 per share, from $21.2 million, or $0.31 per share, a year earlier.
- Gross margin reached 57%, up 270 basis points compared to the third quarter of 2025.
- Adjusted EBITDA climbed to $18.0 million, or 6% of sales, versus $2.8 million a year ago.
- The company reaffirmed full-year 2026 sales guidance of $1.065 billion to $1.085 billion.
- Worldwide pump shipments totaled roughly 33,000, including nearly 23,000 in the United States.
Earnings Context and Why It Matters
Tandem Diabetes Care's third-quarter results arrived at a pivotal moment in its business-model transformation. The company is shifting U.S. sales toward a pay-as-you-go pharmacy channel, which reduces upfront pump revenue but is designed to improve long-term economics and expand patient access. I am watching closely to see whether margin gains and international growth can offset the near-term revenue headwinds from this transition. With the stock having trailed the broader market earlier in 2026, this report was also a key test of whether TNDM's profitability roadmap is on track. From what I see, the PayGo shift remains the central theme investors are evaluating.
Reported Results
TNDM reported third quarter 2026 worldwide sales of $283.7 million, up 14% from $249.3 million in the prior-year period, exceeding consensus estimates of roughly $264 million. U.S. sales rose 9% to $191.0 million, while international sales jumped 26% to $92.6 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company posted a net loss of $7.1 million, or $0.10 per share, a meaningful improvement from a net loss of $21.2 million, or $0.31 per share, a year ago. The per-share result came in well ahead of the consensus estimate of a larger loss.
Gross margin expanded to 57%, up 270 basis points, while the operating loss narrowed to $2.4 million from $22.9 million. Adjusted EBITDA reached $18.0 million, or 6% of sales, compared with $2.8 million, or 1% of sales, in the year-ago quarter.
Management reaffirmed full-year 2026 guidance, including sales of $1.065 billion to $1.085 billion and gross margin of approximately 56% to 57% of sales.
Market Reaction and Investor Sentiment
Shares moved higher following the report, reflecting investor enthusiasm for the revenue beat and the continued margin expansion. The sharp narrowing of the net loss and the rebound in adjusted EBITDA reinforced confidence that Tandem's PayGo transition and international go-direct strategy are beginning to deliver improved profitability. The reaffirmed full-year guidance also removed a key source of uncertainty heading into the fourth quarter.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should watch several themes tied to Tandem's transformation. First, the pace of PayGo pharmacy adoption remains central. Management reported that about 15% of U.S. sales now flow through the pharmacy channel, with formulary coverage reaching approximately 50% of U.S. lives. How quickly this mix shifts will influence near-term revenue timing and long-term gross margin. One thing that stands out is the potential for this channel to support broader access over time.
Second, international expansion is gaining momentum. The t:slim X2 system's compatibility with the Abbott FreeStyle Libre 3 Plus sensor is now available in 11 international markets, and Tandem Mobi is available in 12 countries. Continued rollout into new direct markets could support revenue growth, though transitions away from distributors can create temporary headwinds. In my view, the international segment offers a meaningful growth lever here.
Finally, cost discipline and product mix will determine whether Tandem sustains its margin trajectory. Management has signaled an expectation that gross margins could scale toward the upper end of guidance as direct-channel pricing and higher Mobi volumes take hold. Balancing these drivers against competitive pressures in automated insulin delivery will be key for investors tracking the next several quarters. I cross-checked the competitive landscape using Tickeron’s AI Trend Prediction Engine to confirm the positioning.
Leveraging AI Tools in My Analysis
In my regular research workflow, Tickeron’s AI Screener has become a useful resource for quickly filtering opportunities and comparing metrics across the diabetes care space. It allows me to scan for technical patterns, fundamentals, and performance signals in a more efficient way than manual reviews alone. This helps confirm whether a name like TNDM stands out relative to peers before digging deeper into the filings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TNDM's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for TNDM turned positive on October 02, 2026. Looking at past instances where TNDM's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on TNDM as a result. In 60 of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
TNDM moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TNDM crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 72%.
Following a +2.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNDM advanced for three days, in 210 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 107 of 159 cases where TNDM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for TNDM moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 54 cases where TNDM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNDM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TNDM broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. TNDM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.600) is normal, around the industry mean (4.338). P/E Ratio (-19.989) is within average values for comparable stocks, (1.324). Projected Growth (PEG Ratio) (9.850) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (1.150) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNDM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of medical devices for the treatment of diabetes
Industry MedicalNursingServices
Advertisement